2024
Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: the TRANSFORM-HF trial
Nouhravesh N, Clare R, Wojdyla D, Anstrom K, Velazquez E, Greene S, Pitt B, Mentz R, Psotka M. Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: the TRANSFORM-HF trial. European Heart Journal 2024, 45: ehae666.1068. DOI: 10.1093/eurheartj/ehae666.1068.Peer-Reviewed Original ResearchKCCQ-CSSTertile 1Diuretic doseHeart failureAll-cause mortalityTertile 3Tertile 2Diuretic strategyKansas City Cardiomyopathy Questionnaire Clinical Summary ScoreDoses of loop diureticsHigh doses of furosemideComposite all-cause mortalityBaseline to monthDose of furosemideClinical summary scoreRisk of adverse eventsInteraction p valuePost hoc analysisFurosemide equivalentsLoop diureticsOpen-labelMedian ageNo significant differenceClinical outcomesStudy endpoint
2017
Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients
Sun JL, Boyle SH, Samad Z, Babyak MA, Wilson JL, Kuhn C, Becker RC, Ortel TL, Williams RB, Rogers JG, O’Connor C, Velazquez EJ, Jiang W. Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients. European Journal Of Preventive Cardiology 2017, 24: 591-599. PMID: 28067532, PMCID: PMC6093615, DOI: 10.1177/2047487316686435.Peer-Reviewed Original ResearchMeSH KeywordsAgedCitalopramDisease-Free SurvivalFemaleHumansMaleMental HealthMiddle AgedMultivariate AnalysisMyocardial IschemiaProportional Hazards ModelsRisk AssessmentRisk FactorsSelective Serotonin Reuptake InhibitorsStress, PsychologicalStroke VolumeTime FactorsTreatment OutcomeVentricular Dysfunction, LeftVentricular Function, LeftConceptsMental stress-induced myocardial ischemiaMajor adverse cardiovascular eventsAdverse cardiovascular eventsLeft ventricular ejection fraction changeVentricular ejection fraction changeStable ischemic heart diseaseIschemic heart disease patientsLeft ventricular ejection fractionStress-induced myocardial ischemiaEjection fraction changesVentricular ejection fractionIschemic heart diseaseCardiovascular eventsHeart disease patientsMyocardial ischemiaEjection fractionStudy endpointDisease patientsHeart diseaseMental Stress–Induced Myocardial IschemiaStress-induced left ventricular dysfunctionFuture adverse cardiovascular eventsLeft ventricular dysfunctionHeart failure statusAssociation of indices
2004
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial
Jamerson K, Bakris G, Wun C, Dahlöf B, Lefkowitz M, Manfreda S, Pitt B, Velazquez E, Weber M. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial. American Journal Of Hypertension 2004, 17: 793-801. PMID: 15363822, DOI: 10.1016/j.amjhyper.2004.05.004.Peer-Reviewed Original ResearchConceptsSystolic Hypertension (ACCOMPLISH) trialCardiovascular eventsBlood pressureHypertension trialsCombination therapyOptimal BP controlPrimary study endpointCalcium channel blockersClass of drugsBP controlCardiovascular outcomesHypertensive patientsPrimary endpointCardiovascular mortalityStudy endpointACE inhibitorsHypertension managementFirst patientClinical eventsAntihypertensive combinationsRisk factorsSuch therapyRecent guidelinesDrug classesVasculoprotective properties